[Initial results of multicenter, randomized, controlled therapy studies for ANCA-associated vasculitis].
de Groot
K
K
European Vasculitis Study Group (EUVAS), Abt. für Nephrologie, Med. Hochschule Hannover, Germany.
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008134:Long-Term Care; D015337:Multicenter Studies as Topic; D010348:Patient Care Team; D010951:Plasma Exchange; D011239:Prednisolone / Q000008:administration & dosage*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone